Roivant Sciences reported that mosliciguat achieved its primary and key secondary endpoints in a 16-week Phase 2 study in pulmonary hypertension, supporting a potential expansion of treatment options in a serious cardiopulmonary indication. The company said mosliciguat reduced pulmonary vascular resistance by 56% versus placebo and improved the six-minute walk distance metric by 35 meters relative to placebo-adjusted results. It also cited reductions in NT-proBNP, a blood marker of heart failure. The Phase 2 success adds clinical validation for Roivant’s inhaled approach and could support future development decisions. Coverage also linked the readout to financial implications for the company, which has been seeking a stronger pipeline position. In the broader context, the update highlights how mid-stage outcomes continue to drive near-term biotech valuation and signaling about next study designs.